These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27236132)

  • 1. Safety Issues in Iron Treatment in CKD.
    Vaziri ND
    Semin Nephrol; 2016 Mar; 36(2):112-8. PubMed ID: 27236132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.
    Vaziri ND
    Am J Kidney Dis; 2013 Jun; 61(6):992-1000. PubMed ID: 23375852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric Citrate in Patients With Chronic Kidney Disease.
    Block GA
    Semin Nephrol; 2016 Mar; 36(2):130-5. PubMed ID: 27236135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
    Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxic effects of IV iron preparations in CKD patients.
    Vaziri ND
    Nephrol News Issues; 2014 Feb; 28(2):4-5. PubMed ID: 24649744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
    Shah HH; Hazzan AD; Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron Treatment Strategies in Dialysis-Dependent CKD.
    Pandey R; Daloul R; Coyne DW
    Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The iron story: red smoke and magnetism?
    Wish JB
    Nephrol News Issues; 2014 Feb; 28(2):2-3. PubMed ID: 24649743
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.
    Van Buren P; Velez RL; Vaziri ND; Zhou XJ
    Int Urol Nephrol; 2012 Apr; 44(2):499-507. PubMed ID: 21744260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron Treatment Strategies in Nondialysis CKD.
    Macdougall IC
    Semin Nephrol; 2016 Mar; 36(2):99-104. PubMed ID: 27236130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron toxicity: relevance for dialysis patients.
    Fishbane S; Mathew A; Vaziri ND
    Nephrol Dial Transplant; 2014 Feb; 29(2):255-9. PubMed ID: 24166458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients.
    Kshirsagar AV; Li X
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):292-297. PubMed ID: 31477259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease.
    Singh N; Agarwal AK
    Clin Nephrol; 2012 Mar; 77(3):188-94. PubMed ID: 22377249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.